Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study

NCT02647112 is registered in ClinicalTrials.gov with Nucleix Ltd. as lead sponsor.

NCT NCT02647112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02647112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study
Lead sponsor
Nucleix Ltd.
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2015
Completion date
December 31, 2020
Enrollment
1,050 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer